NASDAQ:GEMP - Gemphire Therapeutics Stock Price, Price Target & More

$5.86 -0.07 (-1.18 %)
(As of 04/23/2018 04:50 AM ET)
Previous Close$5.86
Today's Range$5.79 - $5.94
52-Week Range$5.55 - $21.59
Volume24,750 shs
Average Volume56,710 shs
Market Capitalization$83.40 million
P/E Ratio-1.81
Dividend YieldN/A
Beta4.07

About Gemphire Therapeutics (NASDAQ:GEMP)

Gemphire Therapeutics logoGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH). It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. The company is headquartered in Livonia, Michigan.

Receive GEMP News and Ratings via Email

Sign-up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GEMP
CUSIPN/A
Phone734-245-1700

Debt

Debt-to-Equity Ratio2.20%
Current Ratio2.97%
Quick Ratio2.97%

Price-To-Earnings

Trailing P/E Ratio-1.81
Forward P/E Ratio-2.17
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.37 per share
Price / Book15.84

Profitability

EPS (Most Recent Fiscal Year)($3.23)
Net Income$-33,410,000.00
Net MarginsN/A
Return on Equity-216.63%
Return on Assets-125.70%

Miscellaneous

Employees18
Outstanding Shares14,230,000

How to Become a New Pot Stock Millionaire

Gemphire Therapeutics (NASDAQ:GEMP) Frequently Asked Questions

What is Gemphire Therapeutics' stock symbol?

Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."

How were Gemphire Therapeutics' earnings last quarter?

Gemphire Therapeutics (NASDAQ:GEMP) issued its earnings results on Thursday, March, 15th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.09. View Gemphire Therapeutics' Earnings History.

When is Gemphire Therapeutics' next earnings date?

Gemphire Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Gemphire Therapeutics.

What price target have analysts set for GEMP?

5 Wall Street analysts have issued 1-year price objectives for Gemphire Therapeutics' shares. Their predictions range from $18.00 to $31.00. On average, they anticipate Gemphire Therapeutics' stock price to reach $25.80 in the next year. View Analyst Ratings for Gemphire Therapeutics.

What are Wall Street analysts saying about Gemphire Therapeutics stock?

Here are some recent quotes from research analysts about Gemphire Therapeutics stock:
  • 1. According to Zacks Investment Research, "Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company's product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. " (3/21/2018)
  • 2. Canaccord Genuity analysts commented, "We believe gemcabene’s 40% hsCRP reduction is very meaningful, especially given that Novartis canikinumab reduced hsCRP and lowered Major Adverse Cardiac Events (MACE). In our view, gemcabene has lowering effects on important biomarkers beyond LDL, including triglycerides and hsCRP, differentiating the drug from competitors. Continue to anticipate positive INDIGO-1 data in 2018 We expect gemcabene to show a statistically significant reduction in triglycerides in the INDIGO-1 study in 2018, providing a major catalyst for shares to move higher. Importantly, many drugs can lower LDL cholesterol, but some have no effect on triglycerides, such as PCSK9 therapies." (10/13/2017)

Who are some of Gemphire Therapeutics' key competitors?

Who are Gemphire Therapeutics' key executives?

Gemphire Therapeutics' management team includes the folowing people:
  • Dr. Charles L. Bisgaier Ph.D., Co-Founder, Chairman and Chief Scientific Officer (Age 64)
  • Dr. Steven R. Gullans, Interim Chief Exec. Officer, Interim Pres & Director (Age 65)
  • Mr. Jeffrey S. Mathiesen, Chief Financial Officer and Sec. (Age 57)
  • Mr. Seth Reno MBA, Chief Commercial Officer (Age 51)
  • Dr. Lee Golden M.D., Chief Medical Officer (Age 50)

When did Gemphire Therapeutics IPO?

(GEMP) raised $30 million in an initial public offering (IPO) on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

Has Gemphire Therapeutics been receiving favorable news coverage?

Press coverage about GEMP stock has trended somewhat positive on Monday, Accern reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gemphire Therapeutics earned a coverage optimism score of 0.04 on Accern's scale. They also assigned media stories about the company an impact score of 44.21 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Gemphire Therapeutics?

Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gemphire Therapeutics' stock price today?

One share of GEMP stock can currently be purchased for approximately $5.86.

How big of a company is Gemphire Therapeutics?

Gemphire Therapeutics has a market capitalization of $83.40 million. The company earns $-33,410,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. Gemphire Therapeutics employs 18 workers across the globe.

How can I contact Gemphire Therapeutics?

Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700.


MarketBeat Community Rating for Gemphire Therapeutics (GEMP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  280
MarketBeat's community ratings are surveys of what our community members think about Gemphire Therapeutics and other stocks. Vote "Outperform" if you believe GEMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEMP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Gemphire Therapeutics (NASDAQ:GEMP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Gemphire Therapeutics in the last 12 months. Their average twelve-month price target is $25.80, suggesting that the stock has a possible upside of 340.27%. The high price target for GEMP is $31.00 and the low price target for GEMP is $18.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.80$25.80$24.60$26.00
Price Target Upside: 340.27% upside164.89% upside202.58% upside173.11% upside

Gemphire Therapeutics (NASDAQ:GEMP) Consensus Price Target History

Price Target History for Gemphire Therapeutics (NASDAQ:GEMP)

Gemphire Therapeutics (NASDAQ:GEMP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2018HC WainwrightReiterated RatingBuy$28.00LowView Rating Details
12/22/2017Roth CapitalReiterated RatingBuy$30.00MediumView Rating Details
10/27/2017Piper JaffrayReiterated RatingOverweight -> Overweight$22.00N/AView Rating Details
10/23/2017Canaccord GenuityReiterated RatingBuy$31.00N/AView Rating Details
8/8/2017Jefferies GroupLower Price TargetBuy -> Buy$32.00 -> $18.00HighView Rating Details
9/16/2016Royal Bank of CanadaReiterated RatingOutperform$25.00N/AView Rating Details
9/6/2016LaidlawInitiated CoverageBuy$20.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Gemphire Therapeutics (NASDAQ:GEMP) Earnings History and Estimates Chart

Earnings by Quarter for Gemphire Therapeutics (NASDAQ:GEMP)

Gemphire Therapeutics (NASDAQ:GEMP) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.7 EPS
Next Year EPS Consensus Estimate: $-3.56 EPS

Gemphire Therapeutics (NASDAQ GEMP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.63)N/AView Earnings Details
3/15/2018Q4 2017($0.72)($0.63)ViewN/AView Earnings Details
11/13/2017Q3 2017($0.68)($0.82)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.71)($0.99)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.61)($0.79)ViewN/AView Earnings Details
3/15/201712/31/2016($0.54)($0.78)ViewN/AView Earnings Details
11/2/2016Q316($0.45)($0.56)ViewN/AView Earnings Details
9/14/2016Q2 2016($0.23)($0.42)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Gemphire Therapeutics (NASDAQ:GEMP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Gemphire Therapeutics (NASDAQ GEMP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 34.00%
Institutional Ownership Percentage: 19.75%
Insider Trading History for Gemphire Therapeutics (NASDAQ:GEMP)
Insider Trading History for Gemphire Therapeutics (NASDAQ:GEMP)

Gemphire Therapeutics (NASDAQ GEMP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2018Steven R Ph.D. GullansInsiderBuy71,429$7.00$500,003.00View SEC Filing  
3/10/2017Andy SassineDirectorBuy21,119$9.47$199,996.93136,264View SEC Filing  
8/10/2016David LowenschussInsiderBuy11,120$10.00$111,200.00806,247View SEC Filing  
8/10/2016Jeffrey S MathiesenCFOBuy4,000$10.00$40,000.003,927View SEC Filing  
8/10/2016Mina SoochCEOBuy52,500$10.00$525,000.00693,732View SEC Filing  
8/10/2016Steven R Ph.D. GullansDirectorBuy500,000$10.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Gemphire Therapeutics (NASDAQ GEMP) News Headlines

Source:
DateHeadline
Gemphire Therapeutics (GEMP) Given a $31.00 Price Target by Canaccord Genuity AnalystsGemphire Therapeutics (GEMP) Given a $31.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 15 at 8:22 PM
Gemphire Therapeutics (GEMP) PT Raised to $32.00 at Jefferies GroupGemphire Therapeutics (GEMP) PT Raised to $32.00 at Jefferies Group
www.americanbankingnews.com - April 14 at 3:36 PM
Jefferies Group Cuts Gemphire Therapeutics (GEMP) Price Target to $18.00Jefferies Group Cuts Gemphire Therapeutics (GEMP) Price Target to $18.00
www.americanbankingnews.com - April 12 at 9:00 PM
Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)
finance.yahoo.com - April 12 at 5:44 PM
Gemphire Therapeutics (GEMP) Given Average Rating of "Buy" by BrokeragesGemphire Therapeutics (GEMP) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 12 at 11:47 AM
Gemphire Therapeutics (GEMP) Downgraded by Zacks Investment Research to SellGemphire Therapeutics (GEMP) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - April 7 at 3:52 PM
-$0.63 EPS Expected for Gemphire Therapeutics (GEMP) This Quarter-$0.63 EPS Expected for Gemphire Therapeutics (GEMP) This Quarter
www.americanbankingnews.com - April 7 at 9:53 AM
Gemphire Therapeutics (GEMP) Downgraded by Zacks Investment Research to "Sell"Gemphire Therapeutics (GEMP) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 27 at 11:28 PM
Zacks Investment Research Downgrades Gemphire Therapeutics (GEMP) to HoldZacks Investment Research Downgrades Gemphire Therapeutics (GEMP) to Hold
www.americanbankingnews.com - March 21 at 11:12 PM
 Brokerages Anticipate Gemphire Therapeutics Inc (GEMP) to Announce -$0.63 Earnings Per Share Brokerages Anticipate Gemphire Therapeutics Inc (GEMP) to Announce -$0.63 Earnings Per Share
www.americanbankingnews.com - March 21 at 12:36 PM
Gemphire Therapeutics Inc (GEMP) Given Consensus Rating of "Buy" by AnalystsGemphire Therapeutics Inc (GEMP) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 18 at 11:56 AM
Otonomy (OTIC) vs. Gemphire Therapeutics (GEMP) Financial ContrastOtonomy (OTIC) vs. Gemphire Therapeutics (GEMP) Financial Contrast
www.americanbankingnews.com - March 17 at 1:43 PM
Edited Transcript of GEMP earnings conference call or presentation 15-Mar-18 8:30pm GMTEdited Transcript of GEMP earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 6:33 PM
8 Stocks Moving In Thursdays After-Hours Session | Benzinga - Benzinga8 Stocks Moving In Thursday's After-Hours Session | Benzinga - Benzinga
www.benzinga.com - March 16 at 8:13 AM
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year ... - NasdaqGemphire Therapeutics Reports Fourth Quarter and Fiscal Year ... - Nasdaq
www.nasdaq.com - March 16 at 8:13 AM
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results - GlobeNewswire (press release)Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 16 at 8:13 AM
Gemphire Therapeutics (GEMP) Announces  Earnings Results, Beats Estimates By $0.09 EPSGemphire Therapeutics (GEMP) Announces Earnings Results, Beats Estimates By $0.09 EPS
www.americanbankingnews.com - March 15 at 6:30 PM
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial ResultsGemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
finance.yahoo.com - March 15 at 6:18 PM
Gemphire Therapeutics Inc (NASDAQ:GEMP): Are Analysts Optimistic?Gemphire Therapeutics Inc (NASDAQ:GEMP): Are Analysts Optimistic?
finance.yahoo.com - March 15 at 6:18 PM
Gemphire Therapeutics (GEMP) Set to Announce Quarterly Earnings on ThursdayGemphire Therapeutics (GEMP) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 14 at 12:20 PM
Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15
finance.yahoo.com - March 13 at 7:22 PM
M&A, Innovation & New Drugs to Drive Pharma Stocks - NasdaqM&A, Innovation & New Drugs to Drive Pharma Stocks - Nasdaq
www.nasdaq.com - March 9 at 8:14 AM
Whats in the Cards for Merck KGaA (MKGAF) in Q4 Earnings?What's in the Cards for Merck KGaA (MKGAF) in Q4 Earnings?
finance.yahoo.com - March 7 at 6:39 PM
 Brokerages Anticipate Gemphire Therapeutics Inc (GEMP) Will Announce Earnings of -$0.72 Per Share Brokerages Anticipate Gemphire Therapeutics Inc (GEMP) Will Announce Earnings of -$0.72 Per Share
www.americanbankingnews.com - March 4 at 5:08 AM
Gemphire Therapeutics Inc (GEMP) Short Interest UpdateGemphire Therapeutics Inc (GEMP) Short Interest Update
www.americanbankingnews.com - March 4 at 1:40 AM
Gemphire Expert Panel Call on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH to be RescheduledGemphire Expert Panel Call on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH to be Rescheduled
finance.yahoo.com - February 27 at 5:58 PM
Gemphire Therapeutics Inc (GEMP) Receives Average Recommendation of "Buy" from BrokeragesGemphire Therapeutics Inc (GEMP) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 21 at 12:02 PM
Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASHGemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH
feeds.benzinga.com - February 21 at 7:09 AM
Gemphire Therapeutics (GEMP) Rating Increased to Buy at Zacks Investment ResearchGemphire Therapeutics (GEMP) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - February 15 at 11:22 PM
Jefferies Group Comments on Gemphire Therapeutics Incs FY2018 Earnings (GEMP)Jefferies Group Comments on Gemphire Therapeutics Inc's FY2018 Earnings (GEMP)
www.americanbankingnews.com - February 15 at 11:40 AM
Gemphire Therapeutics Inc (GEMP) Interim President & CEO Steven R. Ph.d. ...Gemphire Therapeutics Inc (GEMP) Interim President & CEO Steven R. Ph.d. ...
finance.yahoo.com - February 13 at 9:22 AM
Insider Buying: Gemphire Therapeutics Inc (GEMP) Insider Purchases 71,429 Shares of StockInsider Buying: Gemphire Therapeutics Inc (GEMP) Insider Purchases 71,429 Shares of Stock
www.americanbankingnews.com - February 12 at 6:30 PM
Gemphire Therapeutics (GEMP) Prices 3.14M Common Stock Offering at $7/ShareGemphire Therapeutics (GEMP) Prices 3.14M Common Stock Offering at $7/Share
www.streetinsider.com - February 9 at 3:50 PM
ValuEngine Lowers Gemphire Therapeutics (GEMP) to Strong SellValuEngine Lowers Gemphire Therapeutics (GEMP) to Strong Sell
www.americanbankingnews.com - February 8 at 10:34 PM
Gemphire Announces Pricing of $22 Million Public Offering of Common StockGemphire Announces Pricing of $22 Million Public Offering of Common Stock
finance.yahoo.com - February 8 at 3:39 PM
BRIEF-Gemphire Announces Proposed Public Offering Of Common StockBRIEF-Gemphire Announces Proposed Public Offering Of Common Stock
www.reuters.com - February 8 at 8:08 AM
Gemphire Announces Proposed Public Offering of Common StockGemphire Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 8 at 8:08 AM
Head-To-Head Analysis: Gemphire Therapeutics (GEMP) vs. TESARO (TSRO)Head-To-Head Analysis: Gemphire Therapeutics (GEMP) vs. TESARO (TSRO)
www.americanbankingnews.com - February 7 at 9:52 AM
BRIEF-Gemphire Announces Initiation Of Phase 2A Clinical Trial Of Pediatric NAFLDBRIEF-Gemphire Announces Initiation Of Phase 2A Clinical Trial Of Pediatric NAFLD
www.reuters.com - February 2 at 3:44 PM
Gemphire Therapeutics (GEMP) Receives Buy Rating from HC WainwrightGemphire Therapeutics (GEMP) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - February 1 at 1:52 PM
Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
finance.yahoo.com - February 1 at 9:10 AM
Gemphire Therapeutics (GEMP) & Affimed (AFMD) Critical ReviewGemphire Therapeutics (GEMP) & Affimed (AFMD) Critical Review
www.americanbankingnews.com - January 30 at 1:20 PM
Gemphire Therapeutics Inc (GEMP) Receives Consensus Recommendation of "Buy" from BrokeragesGemphire Therapeutics Inc (GEMP) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 27 at 11:56 AM
Gemphire Therapeutics (GEMP) Price Target Raised to $28.00Gemphire Therapeutics (GEMP) Price Target Raised to $28.00
www.americanbankingnews.com - January 26 at 11:48 PM
BRIEF-Gemphire Completes Patient Enrollment In Indigo-1 TrialBRIEF-Gemphire Completes Patient Enrollment In Indigo-1 Trial
www.reuters.com - January 17 at 5:05 PM
Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) PatientsGemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) Patients
finance.yahoo.com - January 17 at 9:46 AM
Gemphire Therapeutics Inc (GEMP) Receives Average Recommendation of "Buy" from AnalystsGemphire Therapeutics Inc (GEMP) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 2 at 12:44 PM
What Should We Expect From Gemphire Therapeutics Inc’s (NASDAQ:GEMP) Earnings In The Years Ahead?What Should We Expect From Gemphire Therapeutics Inc’s (NASDAQ:GEMP) Earnings In The Years Ahead?
finance.yahoo.com - December 30 at 9:41 AM
Zacks: Brokerages Anticipate Gemphire Therapeutics Inc. (GEMP) to Post -$0.72 Earnings Per ShareZacks: Brokerages Anticipate Gemphire Therapeutics Inc. (GEMP) to Post -$0.72 Earnings Per Share
www.americanbankingnews.com - December 27 at 1:08 AM
Gemphire Therapeutics (GEMP) Buy Rating Reiterated at Roth CapitalGemphire Therapeutics' (GEMP) Buy Rating Reiterated at Roth Capital
www.americanbankingnews.com - December 26 at 2:34 PM

SEC Filings

Gemphire Therapeutics (NASDAQ:GEMP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Gemphire Therapeutics (NASDAQ:GEMP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Gemphire Therapeutics (NASDAQ GEMP) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.